jRCT2041240121进行中（未招募）不适用
33-105 : Drug Use-Results Survey of OPDIVO (Cancer of Unknown Primary)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •Patients with cancer of unknown primary, who have recieved OPDIVO for the first time
排除标准
- •Patients who have received OPDIVO previously
结局指标
主要结局
-
[Safety] a) Occurrence status of adverse drug reactions and infections b) Adverse events
次要结局
未报告次要终点
研究者
相似试验
已完成
Unknown
33-104 : Drug Use-Results Survey of OPDIVOnresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemJPRN-jRCT2011230029Kuro Toshihiko100
招募中
不适用
33-505 : Special Drug Use-Results Survey of OPDIVOjRCT2031240473Ono Pharmaceutical Co.,LTD20
Unknown
Unknown
Drug Use-Results Survey of OPDIVO (malignant melanoma)Malignant melanomaJPRN-jRCT1080223217ONO PHARMACEUTICAL CO., LTD.1,700
已完成
Unknown
Drug Use-Results Survey of OPDIVO (head and neck cancer)Head and Neck CancerJPRN-jRCT1080224012ONO PHARMACEUTICAL CO.,LTD.400
已完成
Unknown
Drug Use-Results Survey of OPDIVO (Gastric Cancer)Gastric CancerJPRN-jRCT1080224011ONO PHARMACEUTICAL CO.,LTD.500